Chapter 25: Muscle Relaxants

Muscle Relaxants pharmacology chapter provides a comprehensive overview of skeletal muscle relaxants, detailing their application in treating two distinct neuromuscular abnormalities: muscle spasm, which typically arises acutely from musculoskeletal injury and leads to painful, involuntary contractions often related to localized sensory impulses, and muscle spasticity, a permanent state of sustained contractions resulting from damage to neurons within the central nervous system (CNS), disrupting the necessary balance of inhibitory and excitatory influences. Normal muscle function, posture, and balance depend on integrated control systems, including simple spinal reflexes known as the gamma loop system and higher brain activity modulated by the pyramidal tract (intentional movement) and the extrapyramidal tract (unconscious coordination of activity, posture, and balance). Skeletal muscle relaxants are categorized into two primary groups: Centrally Acting Skeletal Muscle Relaxants (spasmolytics), such as baclofen, carisoprodol, and cyclobenzaprine, which primarily work in the brain and spinal cord by interfering with the reflex arcs that cause spasm, leading to anticipated CNS depression. Baclofen, a prototype gamma-aminobutyric acid analogue, is used for spasticity related to spinal cord injuries but must be tapered slowly upon discontinuation to avoid psychoses or hallucinations. Direct-Acting Skeletal Muscle Relaxants include dantrolene and the botulinum toxins. Dantrolene works directly within muscle fibers by interfering with calcium release from the sarcoplasmic reticulum, thus preventing contraction, and is indicated for spasticity and the treatment or prevention of malignant hyperthermia. A major nursing consideration for dantrolene involves monitoring for potentially fatal hepatocellular injury, which is a heightened risk for women and patients older than 35 years, often preceded by a prodrome syndrome of anorexia, nausea, and fatigue. Botulinum toxins (such as incobotulinumtoxinA and onabotulinumtoxinA) inhibit acetylcholine release at motor nerve terminals, causing localized muscle paralysis, and are used for conditions like cervical dystonia, chronic migraines, and cosmetic improvements, but they carry a black box warning regarding the potential for systemic toxin spread leading to botulism. Nursing care for patients receiving muscle relaxants emphasizes careful assessment for contraindications (e.g., existing hepatic/renal dysfunction, epilepsy, or spasticity contributing to locomotion), the implementation of safety precautions due to CNS side effects like drowsiness and dizziness, and comprehensive patient teaching regarding recognizing and reporting adverse effects. Methocarbamol is noted as the drug of choice for treating severe muscle spasms associated with tetanus in children.